Stock DNA
Pharmaceuticals & Biotechnology
SEK 49 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.36
-119.11%
0.75
Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Jun 2025)
Net Profit:
-23 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-80.79%
0%
-80.79%
6 Months
-77.98%
0%
-77.98%
1 Year
-85.77%
0%
-85.77%
2 Years
-88.82%
0%
-88.82%
3 Years
-95.05%
0%
-95.05%
4 Years
-95.54%
0%
-95.54%
5 Years
-95.17%
0%
-95.17%
Medivir AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-21.94%
EBIT Growth (5y)
0.35%
EBIT to Interest (avg)
-78.25
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.77
EV to EBIT
-0.24
EV to EBITDA
-0.24
EV to Capital Employed
0.56
EV to Sales
5.84
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-239.86%
ROE (Latest)
-122.99%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
1.50
1.10
36.36%
Operating Profit (PBDIT) excl Other Income
-22.60
-36.80
38.59%
Interest
0.20
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-23.30
-36.00
35.28%
Operating Profit Margin (Excl OI)
-15,533.30%
-34,090.90%
1,855.76%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 36.36% vs -45.00% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 35.28% vs -35.34% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3.50
7.60
-53.95%
Operating Profit (PBDIT) excl Other Income
-125.00
-88.60
-41.08%
Interest
0.80
0.90
-11.11%
Exceptional Items
4.70
3.00
56.67%
Consolidate Net Profit
-123.30
-89.30
-38.07%
Operating Profit Margin (Excl OI)
-36,636.70%
-11,965.50%
-2,467.12%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -53.95% vs 72.73% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -38.07% vs -0.56% in Dec 2023
About Medivir AB 
Medivir AB
Pharmaceuticals & Biotechnology
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Company Coordinates 
Company Details
Lunastigen 7 , HUDDINGE None : 141 44
Registrar Details






